Status: Recruiting
Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults
This study aims to demonstrate the safety and immunogenicity of two formulations of the monovalent influenza vaccine candidate A (H5N8) (inactivated, fragmented, and adjuvanted with IB160) from the Instituto Butantan in adults and older adults, to be developed for situations of pandemic, epidemic or outbreak of avian type A/H5 in humans, in the context of pandemic preparedness.
Participants needed: 700
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Butantan InstituteUpdated: Apr 2, 2026Locations: 5
Eligibility criteria
Males and non-pregnant females aged ≥ 18 years at the time of the first study va... [+5]
Having received any vaccine (including seasonal influenza) 28 days prior to the... [+25]